ID   BCP-1
AC   CVCL_0107
SY   BCP1
DR   BTO; BTO:0002728
DR   CLO; CLO_0001905
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-2294
DR   BioSample; SAMN03471861
DR   BioSample; SAMN10987880
DR   Cell_Model_Passport; SIDM01530
DR   Cosmic; 683661
DR   Cosmic; 1238079
DR   Cosmic; 1588555
DR   DepMap; ACH-000923
DR   GEO; GSM634737
DR   GEO; GSM710423
DR   GEO; GSM710439
DR   GEO; GSM886874
DR   GEO; GSM887939
DR   IARC_TP53; 26981
DR   LiGeA; CCLE_346
DR   PharmacoDB; BCP1_81_2019
DR   Progenetix; CVCL_0107
DR   Wikidata; Q4835216
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8705864;
RX   PubMed=9473233;
RX   PubMed=9766492;
RX   PubMed=15613351;
RX   PubMed=17121789;
RX   PubMed=19608668;
RX   PubMed=21685375;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://en.wikipedia.org/wiki/BCP-1_cells
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=BCP-1
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=19608668).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=19608668).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Asn (c.775G>A); Zygosity=Heterozygous (PubMed=19608668; DepMap).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=1.81%; Native American=0.07%; East Asian, North=2%; East Asian, South=0.6%; South Asian=8.1%; European, North=24.92%; European, South=62.51% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11,13
ST   D16S539: 10,11
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   94Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 24
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8705864; DOI=10.1038/nm0896-925;
RA   Gao S.-J., Kingsley L., Li M., Zheng W., Parravicini C., Ziegler J.,
RA   Newton R., Rinaldo C.R., Saah A., Phair J., Detels R., Chang Y.,
RA   Moore P.S.;
RT   "KSHV antibodies among Americans, Italians and Ugandans with and
RT   without Kaposi's sarcoma.";
RL   Nat. Med. 2:925-928(1996).
//
RX   PubMed=9473233; DOI=10.1182/blood.V91.5.1671;
RA   Boshoff C., Gao S.-J., Healy L.E., Matthews S., Thomas A.J.,
RA   Coignet L.J.A., Warnke R.A., Strauchen J.A., Matutes E., Kamel O.W.,
RA   Moore P.S., Weiss R.A., Chang Y.;
RT   "Establishing a KSHV+ cell line (BCP-1) from peripheral blood and
RT   characterizing its growth in Nod/SCID mice.";
RL   Blood 91:1671-1679(1998).
//
RX   PubMed=9766492; DOI=10.1038/sj.leu.2401160;
RA   Drexler H.G., Uphoff C.C., Gaidano G., Carbone A.;
RT   "Lymphoma cell lines: in vitro models for the study of HHV-8+ primary
RT   effusion lymphomas (body cavity-based lymphomas).";
RL   Leukemia 12:1507-1517(1998).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=17121789; DOI=10.1128/JVI.01757-06;
RA   Petre C.E., Sin S.-H., Dittmer D.P.;
RT   "Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus
RT   lymphomas: implications for therapy.";
RL   J. Virol. 81:1912-1922(2007).
//
RX   PubMed=19608668; DOI=10.3324/haematol.2009.007260;
RA   Boulanger E., Marchio A., Hong S.-S., Pineau P.;
RT   "Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin
RT   genes in human herpesvirus 8-associated primary effusion lymphoma.";
RL   Haematologica 94:1170-1174(2009).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//